Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis

Published:2015-12 Issue:12 Volume:45 Page:1266-1273
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Cummins L.¹²,Katikireddi V. S.¹,Shankaranarayana S.¹,Su K. Y. C.¹,Duggan E.¹,Videm V.¹³⁴,Pahau H.¹,Thomas R.¹²

Affiliation:

1. University of Queensland Diamantina Institute; Translational Research Institute; Brisbane Queensland Australia

2. Princess Alexandra Hospital; Brisbane Queensland Australia

3. Department of Laboratory Medicine, Children's and Women's Health; Norwegian University of Science and Technology; Trondheim Norway

4. Department of Immunology and Transfusion Medicine; St Olav University Hospital; Trondheim Norway

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.12896/fullpdf

Reference24 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

2. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade;Smolen;Ann Rheum Dis,2009

3. Myasoedova E Chandran A Ilhan B Major BT Michet CJ Matteson EL et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease 2015

4. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis;Boers;Lancet,1997

5. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications;O'Dell;N Engl J Med,1996

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis;Joint Bone Spine;2024-07

2. Risk Factors Associated with Adverse Events Leading to Methotrexate Withdrawal in Elderly Rheumatoid Arthritis Patients: A Retrospective Cohort Study;Journal of Clinical Medicine;2024-03-24

3. TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis;Trials;2021-07-06

4. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial;LANCET RHEUMATOL;2021

5. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial;The Lancet Rheumatology;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3